Related Experiment Video
Updated: Jun 27, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival
Nathalie A Johnson1, Merrill Boyle, Ali Bashashati
1Department of Pathology and Laboratory Medicine, British Columbia Cancer Agency, Vancouver, Canada.
Blood
|November 26, 2008
Summary
Reduced CD20 expression in diffuse large B-cell lymphoma (DLBCL) is linked to poor survival. Flow cytometry (FCM) is crucial for detecting this, as immunohistochemistry (IHC) may miss it.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- CD20 and CD19 are B cell-specific antigens with heterogeneous expression.
- Flow cytometry (FCM) and immunohistochemistry (IHC) are methods to analyze antigen expression.
Purpose of the Study:
- To investigate the association between CD20 expression and clinical outcomes in diffuse large B-cell lymphoma (DLBCL).
- To evaluate the reliability of FCM versus IHC in detecting reduced CD20 expression.
Main Methods:
- Analyzed CD20 and CD19 expression using FCM and IHC on 272 DLBCL samples.
- Sequenced exon 5 of the MS4A1 gene in 15 samples.
- Correlated antigen expression with patient survival after CHOP or R-CHOP treatment.
Main Results:
- 16% of DLBCL samples showed reduced CD20 expression by FCM.
- Samples with reduced CD20 and bright CD19 expression had significantly inferior survival.
- Reduced CD20 expression by FCM was often missed by IHC, with no MS4A1 gene mutations found.
Conclusions:
- Reduced CD20 expression detected by FCM is a significant predictor of poor survival in DLBCL.
- FCM is essential for assessing CD20 expression in DLBCL due to IHC limitations.
- CD19 and CD20 expression by FCM should be routinely determined for DLBCL patients.
